Highlights
- •EIASM users more often had high LDL level compared to non-EIASM users.
- •Strong EIASM users had nearly 5 times higher odds of high TC level.
- •Strong and weak EIASM users should have careful monitoring of lipid values.
- •VPA users showed lower HDL and higher TG levels compared to those not using VPA.
Abstract
Purpose
Certain anti-seizure medications (ASMs) adversely impact lipid values. Here, we explored
the impact of ASMs on lipid values in adults with epilepsy.
Methods
A total of 228 adults with epilepsy were divided into four groups based on ASMs used:
strong EIASMs, weak EIASMs, non-EIASMs, and no ASMs. Demographic information, epilepsy-specific
clinical history, and lipid values were obtained through chart review.
Results
While there was no significant difference in lipid values between groups, there was
a significant difference in the proportion of participants with dyslipidemia. Specifically,
more participants exhibited elevated low-density lipoprotein (LDL) level in the strong
EIASM group compared to the non-EIASM group (46.7% vs 18%, p < 0.05). In addition, more participants showed elevated LDL level in the weak EIASM
group compared to the non-EIASM group (38% vs 18%, p < 0.05). Users of strong EIASMs showed greater odds of high LDL level (OR 5.734,
p = 0.005) and high total cholesterol level (OR 4.913, p = 0.008) compared to users of non-EIASMs. When we analyzed the impact of individual
ASMs used by more than 15% of the cohort on lipid levels, participants using valproic
acid (VPA) showed lower high-density lipoprotein (p = 0.002) and higher triglyceride levels (p = 0.002) compared to participants not using VPA.
Conclusion
Our study demonstrated a difference in the proportion of participants with dyslipidemia
between ASM groups. Thus, adults with epilepsy using EIASMs should have careful monitoring
of lipid values to address the risk of cardiovascular disease.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Epilepsy & BehaviorAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Early identification of refractory epilepsy.N Engl J Med. 2000; 342: 314-319https://doi.org/10.1056/NEJM200002033420503
- Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study.JAMA Neurol. 2018; 75: 279-286https://doi.org/10.1001/jamaneurol.2017.3949
- Influence of antiepileptic drugs on serum lipid levels in adult epilepsy patients.Epilepsy Res. 2016; 127: 101-106https://doi.org/10.1016/j.eplepsyres.2016.08.027
- Enzyme induction with antiepileptic drugs: Cause for concern?.Epilepsia. 2013; 54: 11-27https://doi.org/10.1111/j.1528-1167.2012.03671.x
- Antiseizure Medications for Adults with Epilepsy: A Review.JAMA - J Am Med Assoc. 2022; 327: 1269-1281https://doi.org/10.1001/jama.2022.3880
- Evaluation of effect of antiepileptic drugs on serum lipid profile among young adults with epilepsy in a tertiary care hospital in Pondicherry.J Clin Diagnostic Res. 2014; 8https://doi.org/10.7860/JCDR/2014/8744.4682
- The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy.Med Sci Monit. 2004; 10: 50-53
- The effects of antiepileptic drugs on vascular risk factors: A narrative review.Seizure. 2014; 23: 677-684https://doi.org/10.1016/j.seizure.2014.05.011
- Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.Acta Neurol Scand. 2010; 122: 30-33https://doi.org/10.1111/j.1600-0404.2010.01372.x
- Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic review.Epilepsy Res. 2015; 113: 44-67https://doi.org/10.1016/j.eplepsyres.2015.03.002
- Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular.J Am Soc Echocardiogr. 2008; 21: 93-111https://doi.org/10.1016/j.echo.2007.11.011
- Usefulness of coronary and carotid imaging rather than traditional atherosclerotic risk factors to identify firefighters at increased risk for cardiovascular disease.Am J Cardiol. 2014; 113: 1499-1504https://doi.org/10.1016/j.amjcard.2014.02.003
- Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults.N Engl J Med. 1999; 340: 14-22https://doi.org/10.1056/NEJM199901073400103
- Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data.Lancet. 2012; 379: 2053-2062https://doi.org/10.1016/S0140-6736(12)60441-3
- Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis.Epilepsia. 2012; 53: 120-128https://doi.org/10.1111/j.1528-1167.2011.03316.x
- Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy.Epilepsy Res. 2007; 74: 183-192https://doi.org/10.1016/j.eplepsyres.2007.03.010
- Polycystic ovaries, obesity and insulin resistance in women with epilepsy: A comparative study of carbamazepine and valproic acid in 105 women.J Neurol. 2002; 249: 835-841https://doi.org/10.1007/s00415-002-0731-3
- Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy.Epilepsia. 2013; 54: e146-e149https://doi.org/10.1111/epi.12338
- Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly.Epilepsia. 2018; 59: 1899-1907https://doi.org/10.1111/epi.14554
- Ketogenic diets for drug-resistant epilepsy (Review).Cochrane Database Syst Rev. 2018; 11https://doi.org/10.1002/14651858.CD001903.pub4
- Ketone bodies in epilepsy.J Neurochem. 2012; 121: 28-35https://doi.org/10.1111/j.1471-4159.2012.07670.x
- The role for ketogenic diets in epilepsy and status epilepticus in adults.Clin Neurophysiol Pract. 2017; 2: 154-160https://doi.org/10.1016/j.cnp.2017.06.001
- Ketogenic diet for treatment of intractable epilepsy in adults: A meta-analysis of observational studies.Epilepsia Open. 2018; 3: 9-17https://doi.org/10.1002/epi4.12098
- Modified atkins diet in adult patients with refractory epilepsy: A controlled randomized clinical trial.Iran J Neurol. 2017; 16: 72-77https://doi.org/10.1111/epi.13241
- Improving compliance in adults with epilepsy on a modified Atkins diet : A randomized trial.Seizure Eur J Epilepsy. 2018; 60: 132-138https://doi.org/10.1016/j.seizure.2018.06.019
- Effect of modified Atkins diet in adults with drug-resistant focal epilepsy: A randomized clinical trial.Epilepsia. 2018; 59: 1567-1576https://doi.org/10.1111/epi.14457
- Six-month effects of modified Atkins diet implementation on indices of cardiovascular disease risk in adults with epilepsy.Nutr Neurosci. 2021; : 1-10https://doi.org/10.1080/1028415X.2021.1875301
- Impact of the modified Atkins diet on cardiovascular health in adults with epilepsy.Epilepsy Behav. 2018; 79: 82-86https://doi.org/10.1016/j.yebeh.2017.10.035
- International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies.Neurol Clin Pract. 2021; 11: 385-397https://doi.org/10.1212/CPJ.0000000000001007
- Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 522-530https://doi.org/10.1111/epi.13670
- Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.JAMA. 2013; 310: 2061-2068https://doi.org/10.1001/jama.2013.280532
- Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).J Am Med Assoc. 2001; 285: 2486-2497https://doi.org/10.1001/jama.285.19.2486
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2019; 140https://doi.org/10.1161/CIR.0000000000000677
- 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines.Circulation. 2014; 129https://doi.org/10.1161/01.cir.0000437741.48606.98
- Dietary DRI Reference Intakes.National Academies Press, 2006 (doi:10.17226/11537)
- Therapeutic Monitoring of Antiepileptic.Drugs. 2020; Vol 7https://doi.org/10.1016/B978-0-444-64066-6.00010-1
- Atlas of Epilepsies.Atlas of Epilepsies. Patsalos 2005, 2010 (doi:10.1007/978-1-84882-128-6)
- Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.Epilepsia. 2008; 49: 1123-1141https://doi.org/10.1111/j.1528-1167.2008.01665.x
- Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.Pharmacotherapy. 2012; 32: 340-353https://doi.org/10.1002/j.1875-9114.2012.01028.x
- Effects of lacosamide and carbamazepine on lipids in a randomized trial.Epilepsia. 2020; 61: 2696-2704https://doi.org/10.1111/epi.16745
- Clobazam therapeutic drug monitoring: A comprehensive review of the literature with proposals to improve future studies.Ther Drug Monit. 2013; 35: 30-47https://doi.org/10.1097/FTD.0b013e31827ada88
Article info
Publication history
Published online: May 25, 2023
Accepted:
May 11,
2023
Received in revised form:
May 9,
2023
Received:
March 8,
2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
